Michael S. Kiernan

Sep 13, 2024 | radcliffecardiology.com | Dipti Itchhaporia |Francisco Lopez-Jimenez |David Ouyang |Michael S. Kiernan

Video Published: Views: 8 Likes: 0 Average (ratings) In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia welcomes two leading experts in artificial intelligence in cardiology: Dr David Ouyang from Cedars-Sinai Medical Center in Los Angeles, and Dr Francisco Lopez-Jiminez from the Mayo Clinic in Rochester, MN. Together, they explore the role of artificial intelligence in cardiology, from diagnostics to personalized treatment strategies.

May 15, 2024 | cfrjournal.com | Harriette Van Spall |Mikhail Kosiborod |Nicolas Girerd |Michael S. Kiernan

HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.

May 14, 2024 | cfrjournal.com | Harold Bays |Michael S. Kiernan |Finn Gustafsson |Ahmad Masri

HFA 2024 — Investigator, Prof Nicolas Girerd (University Hospital of Nancy, FR) joins us to discuss the findings from the TELESAT study (NCT06312501). This multicenter observational longitudinal cohort study investigated whether a Remote Patient Monitoring (RPM) program (Satelia®Cardio, Satelia) is able to prevent cardiac decompensation by detecting weak signals of decompensation early in patients with chronic heart failure in France.

May 13, 2024 | cfrjournal.com | Muthiah Vaduganathan |Nicolas Girerd |Michael S. Kiernan |Finn Gustafsson

HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the findings from a study of four large-scale placebo controlled-trials investigating the timing of cardio-kidney protection with SGLT2 inhibitors. 4 trials that sampled distinct patient populations were enrolled in the trial - the CANVAS program, the CREDENCE trial, DAPA-HF and DELIVER.

May 13, 2024 | cfrjournal.com | Muthiah Vaduganathan |Michael S. Kiernan |Harriette Van Spall |Gregg Stone

HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156). ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens.